tickrz reports
Amgen Inc (AMGN)
Healthcare | Drugs
185.70  0.27%
AMGN vs DRUGS SECTOR & S&P 500
VALUATION
AMGNSECTORS&P 500
P/E RATIO16.5940.521.12
EV/EBITDA RATIO9.98133.412.66
P/S RATIO5.896.52.25
P/B RATIO4.217.73.45
QUALITY
RETURN ON EQUITY25.96%15.79%13.64%
RETURN ON CAPITAL31.55%19.38%10.09%
NET MARGIN34.04%14.46%9.73%
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.49%
PAYOUT RATIO40.08%
3 YR DIVIDEND GROWTH28.62%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
8 OUT OF 9
DEBT-TO-EQUITY111%
INTEREST COVERAGE7.8x
CURRENT RATIO6.07
GROWTH
5 YR EPS GROWTH20.44%
5 YR SPS GROWTH7.65%
5 YR BPS GROWTH11.09%
Amgen Inc News
Does Amgen Inc’s (NASDAQ:AMGN) Debt Level Pose A Problem?
Amgen Inc (NASDAQ:AMGN), a large-cap worth $134.32B, comes to mind for investors seeking a strong and reliable stock investment. Risk-averse investors who are attracted to diversified streams of revenue andRead More...
January 16, 22:14:13 UTC

How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines
Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.
January 16, 21:27:33 UTC

Stocks Hit New High As Apple, Microsoft Rise, But Bitcoin Dives
Stocks marched to new highs Tuesday as Merck, Apple and Microsoft boosted the Dow. But Bitcoin dived.
January 16, 16:00:10 UTC

Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins?
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.
January 16, 15:45:02 UTC

Novartis (NVS) Announces Acceptance of Humira BLA by the FDA
Novartis AG NVS generic arm Sandoz announced that the FDA accepted its Biologics License Application BLA for the proposed biosimilar of AbbVie Inc ABBV Humira The biosimilar was submitted under the 351 k pathway The drug is already approved for the treatment of a number
January 16, 15:12:48 UTC

Will Amgen (AMGN) Continue to Tread Growth Path This Year?
Amgen (AMGN) stock outperformed the industry in 2017. We will have to wait and see if it can keep the momentum alive in 2018.
January 16, 14:55:02 UTC

Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance
Should Investors Be Interested in Vertex Pharmaceuticals in 2018?
January 16, 14:15:02 UTC

Analyst Recommendations for Vertex Pharmaceuticals in January
Should Investors Be Interested in Vertex Pharmaceuticals in 2018?Financial performance in 3Q17
January 16, 12:40:41 UTC

See what the IHS Markit Score report has to say about Amgen Inc.
Amgen Inc NASDAQ/NGS:AMGN
January 15, 13:01:36 UTC

XLV, MRK, AMGN, GILD: ETF Outflow Alert
Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Health Care Select Sector SPDR Fund Symbol XLV where we have detected an approximate 47 4 million dollar outflow that s a 0 3 decrease week over week
January 12, 17:02:51 UTC

Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?
With the rise in demand for immuno oncology drugs and their combinations Merck amp Co Inc s MRK anti PD 1 therapy Keytruda is fast becoming the key top line driver of the pharma giant Keytruda is marketed for many types of cancers and treatment settings including lung cancer
January 12, 16:12:10 UTC

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
January 12, 14:16:02 UTC

See what the IHS Markit Score report has to say about Amgen Inc.
Amgen Inc NASDAQ/NGS:AMGN
January 12, 13:01:38 UTC

Here's Why Arrowhead Pharmaceuticals Inc. Is Up Today
What happened Shares of Arrowhead Pharmaceuticals Inc NASDAQ ARWR a pre clinical stage biotech developing therapies that silence troublesome genes jumped after presentations at this year s J P Morgan Healthcare Conference The stock was up 16 1 as of 2 04 p m EST
January 11, 22:07:39 UTC

Here's Why Arrowhead Pharmaceuticals Inc. Is Up Today
Find out why investors liked what this early-stage biotech had to say at this year's J.P. Morgan Healthcare Conference.
January 11, 20:51:00 UTC


Amgen Inc (AMGN)
Healthcare | Drugs
185.70  0.27%

Does Amgen Inc’s (NASDAQ:AMGN) Debt Level Pose A Problem?
Amgen Inc (NASDAQ:AMGN), a large-cap worth $134.32B, comes to mind for investors seeking a strong and reliable stock investment. Risk-averse investors who are attracted to diversified streams of revenue andRead More...
January 16, 22:14:13 UTC

How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines
Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.
January 16, 21:27:33 UTC

Stocks Hit New High As Apple, Microsoft Rise, But Bitcoin Dives
Stocks marched to new highs Tuesday as Merck, Apple and Microsoft boosted the Dow. But Bitcoin dived.
January 16, 16:00:10 UTC

Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins?
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.
January 16, 15:45:02 UTC

Novartis (NVS) Announces Acceptance of Humira BLA by the FDA
Novartis AG NVS generic arm Sandoz announced that the FDA accepted its Biologics License Application BLA for the proposed biosimilar of AbbVie Inc ABBV Humira The biosimilar was submitted under the 351 k pathway The drug is already approved for the treatment of a number
January 16, 15:12:48 UTC

Will Amgen (AMGN) Continue to Tread Growth Path This Year?
Amgen (AMGN) stock outperformed the industry in 2017. We will have to wait and see if it can keep the momentum alive in 2018.
January 16, 14:55:02 UTC

Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance
Should Investors Be Interested in Vertex Pharmaceuticals in 2018?
January 16, 14:15:02 UTC

Analyst Recommendations for Vertex Pharmaceuticals in January
Should Investors Be Interested in Vertex Pharmaceuticals in 2018?Financial performance in 3Q17
January 16, 12:40:41 UTC

See what the IHS Markit Score report has to say about Amgen Inc.
Amgen Inc NASDAQ/NGS:AMGN
January 15, 13:01:36 UTC

XLV, MRK, AMGN, GILD: ETF Outflow Alert
Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Health Care Select Sector SPDR Fund Symbol XLV where we have detected an approximate 47 4 million dollar outflow that s a 0 3 decrease week over week
January 12, 17:02:51 UTC

Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?
With the rise in demand for immuno oncology drugs and their combinations Merck amp Co Inc s MRK anti PD 1 therapy Keytruda is fast becoming the key top line driver of the pharma giant Keytruda is marketed for many types of cancers and treatment settings including lung cancer
January 12, 16:12:10 UTC

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
January 12, 14:16:02 UTC

See what the IHS Markit Score report has to say about Amgen Inc.
Amgen Inc NASDAQ/NGS:AMGN
January 12, 13:01:38 UTC

Here's Why Arrowhead Pharmaceuticals Inc. Is Up Today
What happened Shares of Arrowhead Pharmaceuticals Inc NASDAQ ARWR a pre clinical stage biotech developing therapies that silence troublesome genes jumped after presentations at this year s J P Morgan Healthcare Conference The stock was up 16 1 as of 2 04 p m EST
January 11, 22:07:39 UTC

Here's Why Arrowhead Pharmaceuticals Inc. Is Up Today
Find out why investors liked what this early-stage biotech had to say at this year's J.P. Morgan Healthcare Conference.
January 11, 20:51:00 UTC